A new report has just been released, aiming to evaluate the market in pediatric combination vaccines. Based on the pertussis antigen component, pediatric combination vaccines can be either DTaP (acellular pertussis) or DTwP (whole-cell pertussis). The report’s primary focus is on aP-based combination vaccines.
The study analyzes global volumes and utilization trends for different types of combination vaccines, including hexavalent, pentavalent, and preschool booster vaccines.
Get an overview of the report below, and click the button to download a full copy:
Combination vaccines immunise infants against diphtheria (D), tetanus (T), pertussis (P), poliomyelitis (IPV), hepatitis B and diseases caused by Haemophilus influenza type b.
Among the pediatric vaccines, we could observe the following facts:
In 2021, despite government efforts, the global immunization rate continued to drop, leaving 25 Mn babies without access to potentially life-saving vaccines. The percentage of newborns who received three doses of the DTP3 declined by 5% between 2019 and 2021, from 86% to 81%.
Multiple factors contributed to the decline: an increase in the number of children living in unstable and conflict-ridden environments where getting immunizations is difficult, low income, an increase in misinformation, lack of education, lack of sanitation, and COVID-19-related problems like service and supply chain disruptions. A sustained catch-up campaign is necessary to avoid missed doses. Maternal vaccination is also important to protect newborns.
WHO and GAVI are implementing initiatives to restore immunization programs. As countries develop economically, they potentially become less eligible for external funding and require increased domestic funding for immunization. In times of crisis, such as during the COVID-19 pandemic, middle-income countries (MIC), which account for an increasing share of unprotected children, might be unable to allocate sufficient resources to immunization programs to ensure that every child receives the available vaccines.
In regards to coverage rates of DTP vaccines in 2021, around 73% of infants didn't receive any doses and 27% were partially vaccinated. Coverage rates vary by region, with the highest in the European Region and the lowest in the African Region.
As a result, many countries are adopting to the shift in type of vaccines for improved immunization, increased safety profile, reduced adverse effects and declining side effects.
Sanofi, the 2021 market leader in DTaP pediatric combination vaccines with 55.4 million doses used in 2021.
The study shows that DTwP vaccines are more commonly used, but there is growing adoption of DTaP-based vaccines, particularly hexavalent vaccines. The market leader in DTaP combination vaccines is Sanofi with 55.4 million doses used in 2021, compared to 16 million doses of GSK's pertussis-based vaccines.
The demand for aP-based combination vaccines varies in public and private markets. In public markets, government financing and immunization schedules affect demand, while in the private market, it is rather availability and affordability that affect demand.
In 2021, aP-based vaccines accounted for 30% of the DTP combination vaccines market and Europe had the largest share of the market by volume.
Based on close examination of cross-category data, the report concludes that Sanofi's vaccine brands, including Hexaxim and Pentaxim, are market leaders in the aP-based pediatric combination vaccines market, with a global share of 74.7% in 2021.
A White Paper To Understand The Market Structure Of Pediatric Pertussis Combination Vaccines Landscape (2021) contains rich insights on worldwide usage patterns for hexavalent, pentavalent and school entry booster vaccines, together with the volumes administered by brand.
Worldwide usage patterns and the volumes administered by brand across aP-based hexavalent, pentavalent and school entry booster vaccines.
Within the last 3 years, advances in Artificial intelligence and Deep learning have brought a major breakthrough in Natural language understanding.
Worldwide usage patterns and the volumes administered by brand across aP-based hexavalent, pentavalent and vaccines.
